Clinical Trial Completion and Study Overview

The NCT02029443 (ACE-CL-001) clinical trial, conducted by AstraZeneca's subsidiary, Acerta Pharma, is a Phase 1/2 trial of acalabrutinib (brand name: Calquence). It was initiated on January 30, 2014, and officially completed on July 15, 2021. This trial was designed to evaluate the safety and long-term efficacy of acalabrutinib as a single-agent therapy in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The final analysis of this long-term follow-up study demonstrates that acalabrutinib can be a long-term treatment option for CLL/SLL as a first- or second-line therapy, providing critical data for regulatory approval.

Outstanding Long-Term Efficacy and Mechanism of Action

Acalabrutinib is a second-generation BTK (Bruton's Tyrosine Kinase) inhibitor that selectively blocks the BTK protein, which is essential for the survival and proliferation of B cells. In the final clinical analysis, the treatment-naive (TN) patient group showed remarkable results, with an overall response rate (ORR) of 97% during a median follow-up period of 73.7 months. The relapsed/refractory (R/R) patient group, with prior treatment experience, also demonstrated excellent disease control, with a median progression-free survival (mPFS) that has not yet been reached after a follow-up of 53 months. This long-term data provides strong clinical evidence that suggests the potential for sustainable cancer suppression beyond transient responses.

Superior Safety Profile Compared to Existing Treatments

A key benefit of this trial is that it significantly improved the non-selective side effects, such as atrial fibrillation and bleeding, which are commonly associated with first-generation BTK inhibitors like ibrutinib. In the treatment-naive patient group, only 10% of patients discontinued treatment due to adverse events, demonstrating excellent tolerability. Furthermore, patients who were intolerant to ibrutinib were able to successfully switch to acalabrutinib and continue treatment, significantly improving their quality of life. This improvement in safety represents a significant milestone in changing the paradigm of managing chronic leukemia, which requires long-term treatment.

Market Competition and Return on Investment

These innovative clinical results led to AstraZeneca's acquisition of a 55% stake in Acerta Pharma in December 2015 for an upfront payment of $2.5 billion and milestone payments of $1.5 billion, totaling $4 billion. Subsequently, the remaining 45% stake was acquired for $3 billion, totaling a $7 billion deal. Calquence received FDA approval for the CLL/SLL indication in November 2019, and as of Q1 2026, global sales increased by 17% year-over-year, exceeding $900 million, establishing it as a key revenue driver. This demonstrates how clinical differentiation in the approximately $10 billion global BTK inhibitor market can lead to significant commercial success and a high return on investment (ROI).

Why This Matters

The ACE-CL-001 Phase 1/2 trial established the clinical foundation for acalabrutinib to lead the second-generation BTK inhibitor market by overcoming the life-threatening side effects, such as atrial fibrillation, associated with first-generation drugs like ibrutinib. The 97% overall response rate (ORR) in treatment-naive patients and the more than six years of excellent long-term follow-up data in this study served as key indicators for subsequent Phase 3 approval and provided a basis for competing with AbbVie's Imbruvica and BeiGene's Brukinsa. The commercial value of AstraZeneca's approximately $7 billion acquisition of Acerta Pharma was demonstrated by Calquence's growth into a blockbuster drug with approximately $3 billion in annual sales in the approximately $10 billion BTK inhibitor market. As the treatment paradigm for chronic lymphocytic leukemia (CLL) expands from single-agent therapy to combination therapy, the excellent safety demonstrated in this trial will be a critical long-term competitive advantage in combination with other targeted therapies.